Tirzepatide: Research Status, Evidence and Regulation
Status: Approved drug Evidence not yet graded
Last reviewed: Data retrieved:
Entry in preparation. Only verified fields are shown. Sections without verified data are hidden
until sources have been reviewed.
Quick facts
| Also known as | Mounjaro, Zepbound, LY3298176 |
|---|---|
| Category | GLP-1 / incretin |
| Research status | Approved drug |
| Overall evidence level | Evidence not yet graded |
Clinical trials snapshot
- Registered studies
- 270
- Most advanced phase
- Phase 4
- Recruiting or not yet recruiting
- 135
- Most recent start
- 2027-12-12
- Most frequent lead sponsor
- Eli Lilly and Company (81)
- Most common status
- Completed
Source: ClinicalTrials.gov, retrieved . Registry searches by name may miss studies that use other identifiers.
Related
Changelog
- — Entry skeleton created.
Last reviewed: Data retrieved: